Back

Effect of coramitug on diuretic use in transthyretin amyloid cardiomyopathy (ATTR CM): a post-hoc analysis from a phase 2 randomised, placebo-controlled study

30 August 2026 (15:15 - 15:45)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy of aldosterone signalling and drug‑related myocardial injury Diuretics ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Stephen Gottlieb

University of Maryland, Baltimore (United States of America)

3 More presentations in this session

Presentation thumbnail
Effect of finerenone on cardiac remodeling and exercise capacity in patients with anterior ST-elevation myocardial infarction underwent primary percutaneous coronary intervention
Doctor S. Sungkar (Semarang, ID)
Abstract Slides Video
Presentation thumbnail
Comparative effectiveness of mineralocorticoid receptor antagonists in cardiorenal and metabolic disease
Associate Professor A. Briasoulis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Development and validation of a Frusemide Card to guide self-titration of oral frusemide in the outpatient setting
Doctor S. Hussin (Kota Bharu, MY)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy of aldosterone signalling and drug‑related myocardial injury

The Event

Event poster

ESC Congress 2026

30 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Tafamidis to treat patients with transthyretin cardiac amyloidosis (ATTR-CM): real-world data from a tertiary centre
30 August 2026
thumbnail
Congress Presentation
Building on the demonstrated functional benefit of tafamidis: association of TTR stabilisation with 6MWT outcomes in ATTR ACT
30 August 2026
thumbnail
Congress Presentation
Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study
19 May 2025
thumbnail
Congress Presentation
Disease progression and outcomes in patients with transthyretin amyloid cardiomyopathy receiving tafamidis
20 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources